Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Ivacaftor in Infants with Cystic Fibrosis
NCT03277196Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2017; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03277196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277196.